A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Amgen
- 18 Mar 2022 Results by deriving Biodistribution data from a NCT02014441 developing a mechanistic model of oncolytic immunotherapy in advanced melanoma treatment, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 08 May 2018 Status changed from active, no longer recruiting to completed.
- 07 Feb 2018 Planned End Date changed from 28 Feb 2018 to 28 Aug 2018.